Immunotherapy plus chemotherapy before surgery for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of an immunotherapy drug (cadonilimab) with chemotherapy before surgery for stomach cancer. The goal is to see if this approach shrinks tumors more effectively and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a type of stomach cancer confirmed by biopsy
- Cancer is in an early-to-middle stage (not spread to distant organs)
- Be healthy enough to have surgery later
- Good blood, kidney, and liver function
- Not have received prior treatment for this cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy before surgery for stomach or gastroesophageal junction cancer. The goal is to shrink the tumor and improve outcomes for patients who are candidates for surgery.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This study tests whether adding cadonilimab (and possibly AK117) to chemotherapy can improve outcomes for people with resectable stomach or stomach–esophagus cancer. It aims to see if this combination works better than chemotherapy alone, while still being safe around surgery.
This trial tests a new combination of immunotherapy (cadonilimab) and chemotherapy before and after surgery for a specific type of advanced stomach or gastroesophageal junction cancer. It aims to see if adding this immunotherapy helps shrink tumors and improve outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.